Immatics N.V.
NASDAQ:IMTXBiotechnology
Healthcare
$5.95 +1.58%
+$0.15 today
- Market cap
- $890.33M
- Beta
- 1.30
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$1.59
52W Low $5.05High $12.41
Volume 0.99M
Average 0.46M
Income Statement
Follow revenue through to earnings.
Revenue
$48.27M
FY 2025 · Annual
-69.0% YoYOperating Income
-$182.02M
FY 2025 · Annual
Net Income
-$196.45M
FY 2025 · Annual
Income Statement
EUR
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 34.76M | 172.83M | 54M | 155.84M | 48.27M |
| Cost of Revenue | 87.57M | 106.78M | 118.66M | 0 | 0 |
| Gross Profit | (52.81M) | 66.05M | (64.67M) | 155.84M | 48.27M |
| Gross Margin | -151.9% | 38.2% | -119.8% | 100.0% | 100.0% |
| Research & Development | 87.57M | 106.78M | 118.66M | 148.08M | 183.83M |
| Selling, General & Admin | 33.81M | 36.12M | 38.2M | 46.45M | 51.18M |
| Operating Expenses | 121.05M | 142.88M | 155.72M | 194.45M | 230.28M |
| Depreciation & Amortization | 5.47M | 6.84M | 7.23M | 12.23M | 12.4M |
| EBITDA | (87.3M) | 50.04M | (88.93M) | 34.46M | (185.09M) |
| EBITDA Margin | -251.1% | 29.0% | -164.7% | 22.1% | -383.5% |
| Operating Income | (86.29M) | 29.95M | (101.73M) | (38.62M) | (182.02M) |
| Operating Margin | -248.2% | 17.3% | -188.4% | -24.8% | -377.1% |
| Interest Income | 133K | 2.48M | 13.85M | 25M | 17.18M |
| Interest Expense | 566K | 1.04M | 831K | 886K | 946K |
| Other Income / Expenses | (7.04M) | 12.08M | 4.73M | 59.96M | (16.42M) |
| Income Before Tax | (93.34M) | 42.04M | (96.99M) | 21.35M | (198.44M) |
| Pre-Tax Margin | -268.5% | 24.3% | -179.6% | 13.7% | -411.1% |
| Income Tax Expense | 0 | 4.55M | 0 | 6.13M | (1.99M) |
| Net Income | (95.06M) | 37.51M | (96.99M) | 15.22M | (196.45M) |
| Net Margin | -273.5% | 21.7% | -179.6% | 9.8% | -407.0% |
| EPS (Basic) | (1.51) | 0.55 | (1.20) | 0.14 | (1.54) |
| EPS (Diluted) | (1.51) | 0.54 | (1.20) | 0.14 | (1.54) |
| 62.91M | 67.22M | 80.55M | 108.7M | 122.35M | |
| 62.91M | 68.82M | 80.55M | 106.8M | 122.35M |
IMTX Earnings Waterfall · TTM
NASDAQ:IMTX · Revenue to Net Income
Key Ratios
EPS$-1.71
Gross Margin100.0%
Net Margin-849.9%
P/E Ratio-4.8
P/S Ratio123.7
Analysis
$37.3M of revenue converted into -$214.4M of net income for the selected period. Gross margin is 100.0% and net margin is -849.9%, showing how much revenue survives after costs and taxes. EPS is $-1.71, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 6-K | 6-K filing | Nov 10, 2026 | |
| 6-K | 6-K filing | Oct 26, 2026 | |
| 6-K | 6-K filing | Oct 23, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 27, 2026 |
How much revenue does IMTX generate?
Immatics N.V. (IMTX) reported $48.27M of revenue in fiscal 2025.
Is IMTX profitable?
Immatics N.V. (IMTX) reported -$196.45M of net income, with a net margin of -407.0%.
Continue the stock analysis
Jump to another research area for this company.